1. Scrip
  2. >>R&D

Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track

 
• By Sten Stovall

Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.

Internal organs
Derazantinib Is In Phase II Testing For Intrahepatic Bile Duct Cancer • Source: Shutterstock

Promising efficacy and safety tolerability shown by derazantinib in an interim analysis of its Phase II registrational study in bile duct cancer has reinforced Basilea Pharmaceutica Ltd. hopes of extending the clinical development program of the pan-fibroblast growth factor receptor inhibitor in other types of FGFR-driven solid tumors, the company said.

Derazantinib (BAL087, formerly ARQ 087) is a Phase III fibroblast growth factor receptor antagonist for intrahepatic cholangiocarcinoma (iCCA), a disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

More from R&D